SG11201503308XA - PRODUCTION OF RECOMBINANT VACCINE IN <i>E. COLI</i> BY ENZYMATIC CONJUGATION - Google Patents
PRODUCTION OF RECOMBINANT VACCINE IN <i>E. COLI</i> BY ENZYMATIC CONJUGATIONInfo
- Publication number
- SG11201503308XA SG11201503308XA SG11201503308XA SG11201503308XA SG11201503308XA SG 11201503308X A SG11201503308X A SG 11201503308XA SG 11201503308X A SG11201503308X A SG 11201503308XA SG 11201503308X A SG11201503308X A SG 11201503308XA SG 11201503308X A SG11201503308X A SG 11201503308XA
- Authority
- SG
- Singapore
- Prior art keywords
- coli
- production
- recombinant vaccine
- enzymatic conjugation
- conjugation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723408P | 2012-11-07 | 2012-11-07 | |
| PCT/EP2013/073266 WO2014072405A1 (en) | 2012-11-07 | 2013-11-07 | Production of recombinant vaccine in e. coli by enzymatic conjugation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201503308XA true SG11201503308XA (en) | 2015-05-28 |
Family
ID=49552366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201503308XA SG11201503308XA (en) | 2012-11-07 | 2013-11-07 | PRODUCTION OF RECOMBINANT VACCINE IN <i>E. COLI</i> BY ENZYMATIC CONJUGATION |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150273043A1 (en) |
| EP (3) | EP2917351B1 (en) |
| JP (2) | JP6412875B2 (en) |
| KR (1) | KR20150079964A (en) |
| CN (1) | CN105008539B (en) |
| AU (2) | AU2013343520B2 (en) |
| BR (1) | BR112015010283A8 (en) |
| CA (2) | CA3125293A1 (en) |
| EA (1) | EA201590705A1 (en) |
| ES (3) | ES2713166T3 (en) |
| IL (1) | IL238586A0 (en) |
| MX (1) | MX366912B (en) |
| SG (1) | SG11201503308XA (en) |
| TR (1) | TR201903066T4 (en) |
| WO (1) | WO2014072405A1 (en) |
| ZA (1) | ZA201503097B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101855380B1 (en) * | 2009-11-19 | 2018-05-08 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
| WO2015052344A1 (en) | 2013-10-11 | 2015-04-16 | Glycovaxyn Ag | Methods of host cell modification |
| WO2015158403A1 (en) * | 2014-04-17 | 2015-10-22 | Glycovaxyn Ag | Modified host cells and uses thereof |
| ES2793023T3 (en) | 2014-08-08 | 2020-11-12 | Glaxosmithkline Biologicals Sa | Modified host cells and hybrid oligosaccharides for use in the production of bioconjugates |
| CA2977561C (en) * | 2015-02-26 | 2022-09-06 | Vaxnewmo Llc | Acinetobacter o-oligosaccharyltransferases and uses thereof |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| CN105963691B (en) * | 2016-07-03 | 2020-05-01 | 查文娟 | Streptococcus pneumoniae vaccine |
| CN106929573B (en) * | 2017-02-21 | 2020-06-09 | 南开大学 | Against Legionella pneumophila type O12wzmAndwecAgene specific nucleotide sequence and application thereof |
| GB201712678D0 (en) * | 2017-08-07 | 2017-09-20 | Glaxosmithkline Biologicals Sa | Process for the manipulation of nucleic acids |
| WO2019043245A1 (en) * | 2017-09-04 | 2019-03-07 | London School Of Hygiene And Tropical Medicine | Microbial cells expressing streptococcal serotypes |
| EP3703745B1 (en) * | 2017-11-04 | 2024-04-10 | Nevada Research & Innovation Corporation | Immunogenic conjugates and methods of use thereof |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| CA3103474A1 (en) | 2018-06-16 | 2019-12-19 | Vaxnewmo Llc | Glycosylated comp pilin variants, methods of making and uses thereof |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| EP3650044A1 (en) * | 2018-11-06 | 2020-05-13 | ETH Zürich | Anti-glycan vaccines |
| WO2020191088A1 (en) * | 2019-03-18 | 2020-09-24 | Janssen Pharmaceuticals, Inc. | Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof |
| EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
| CN111518738B (en) * | 2020-05-08 | 2022-02-08 | 徐州海润生物科技有限公司 | Recombinant bacillus calmette-guerin vaccine and preparation method and application thereof |
| JP2023531242A (en) | 2020-06-25 | 2023-07-21 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Modified Exotoxin A protein |
| WO2023118033A1 (en) | 2021-12-22 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Vaccine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0804582A1 (en) * | 1994-05-16 | 1997-11-05 | The Uab Research Foundation | $i(STREPTOCOCCUS PNEUMONIAE) CAPSULAR POLYSACCHARIDE GENES AND FLANKING REGIONS |
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| US7541043B2 (en) | 2002-01-16 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine for protection against Shigella sonnei disease |
| US20050287628A1 (en) | 2002-03-07 | 2005-12-29 | Markus Aebi | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| DK2311972T3 (en) | 2005-05-11 | 2015-04-27 | Eth Zuerich | Recombinant N-glycosylated proteins from prokaryotic cells |
| JP5782258B2 (en) | 2008-02-20 | 2015-09-24 | グリコヴァキシン アーゲー | Bioconjugates made from prokaryotic recombinant N-glycosylated proteins |
| JP5841044B2 (en) * | 2009-03-23 | 2016-01-06 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | Glycoconjugate vaccine |
| NZ597972A (en) | 2009-07-17 | 2013-06-28 | Ocean Harvest Technology Canada Inc | Natural and sustainable seaweed formula that replaces synthetic additives in fish feed containing ulva lactuca and ascophyllum nodosum |
| SG185433A1 (en) | 2010-05-06 | 2012-12-28 | Glycovaxyn Ag | Capsular gram-positive bacteria bioconjugate vaccines |
| JP6329554B2 (en) * | 2012-10-12 | 2018-05-23 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Host cell modification method |
-
2013
- 2013-11-07 JP JP2015541130A patent/JP6412875B2/en active Active
- 2013-11-07 CN CN201380069524.XA patent/CN105008539B/en active Active
- 2013-11-07 AU AU2013343520A patent/AU2013343520B2/en active Active
- 2013-11-07 CA CA3125293A patent/CA3125293A1/en active Pending
- 2013-11-07 US US14/440,311 patent/US20150273043A1/en not_active Abandoned
- 2013-11-07 EP EP13788753.5A patent/EP2917351B1/en active Active
- 2013-11-07 EP EP18211761.4A patent/EP3508579B1/en active Active
- 2013-11-07 ES ES13788753T patent/ES2713166T3/en active Active
- 2013-11-07 CA CA2889767A patent/CA2889767C/en active Active
- 2013-11-07 ES ES18211761T patent/ES2882282T3/en active Active
- 2013-11-07 KR KR1020157014830A patent/KR20150079964A/en not_active Application Discontinuation
- 2013-11-07 WO PCT/EP2013/073266 patent/WO2014072405A1/en active Application Filing
- 2013-11-07 ES ES18198665T patent/ES2848774T3/en active Active
- 2013-11-07 SG SG11201503308XA patent/SG11201503308XA/en unknown
- 2013-11-07 EP EP18198665.4A patent/EP3444352B1/en active Active
- 2013-11-07 EA EA201590705A patent/EA201590705A1/en unknown
- 2013-11-07 TR TR2019/03066T patent/TR201903066T4/en unknown
- 2013-11-07 BR BR112015010283A patent/BR112015010283A8/en not_active Application Discontinuation
- 2013-11-07 MX MX2015005797A patent/MX366912B/en active IP Right Grant
-
2015
- 2015-05-03 IL IL238586A patent/IL238586A0/en unknown
- 2015-05-06 ZA ZA2015/03097A patent/ZA201503097B/en unknown
-
2017
- 2017-12-20 AU AU2017279688A patent/AU2017279688B2/en active Active
-
2018
- 2018-07-13 US US16/034,906 patent/US10973901B2/en active Active
- 2018-10-01 JP JP2018186302A patent/JP6833785B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201503308XA (en) | PRODUCTION OF RECOMBINANT VACCINE IN <i>E. COLI</i> BY ENZYMATIC CONJUGATION | |
| IL280949A (en) | Ph20 polypeptide variants, formulations and uses thereof | |
| EP2807799B8 (en) | Fallback messaging | |
| EP2818543A4 (en) | Bacillus, hyaluronic acid enzyme, and uses thereof | |
| PL2748300T3 (en) | Enzyme producing bacillus strains | |
| PL2864470T5 (en) | Recombinant microorganisms make biodiesel | |
| SG11201400432VA (en) | Polypeptide vaccine | |
| SG11201502010TA (en) | NOVEL RECOMBINANT <i>BORDETELLA</i> STRAINS | |
| HK1212133A1 (en) | Enhancing aqm to combat wireless losses aqm | |
| EP2809349A4 (en) | Immunogenic composition | |
| HK1199060A1 (en) | Recombinant escherichia coli strains | |
| FR2988733B1 (en) | RECOMBINANT MICROORGANISM | |
| GB201223342D0 (en) | Immunogenic composition | |
| SG11201405100VA (en) | Improvements relating to valves. | |
| HRP20181115T1 (en) | Production of isopropanol by improved recombinant strains | |
| EP2771461A4 (en) | Engineered lower eukaryotic host strains for recombinant protein expression | |
| GB201218660D0 (en) | Immunogenic composition | |
| EP2757155A4 (en) | Novel recombinant bcg vaccine | |
| HK1211323A1 (en) | Dual enzymatic amplification | |
| Reicher et al. | Culture of Shock | |
| AU2013348363B2 (en) | Terminally modified RNA | |
| AU2012904907A0 (en) | Toughened thermosets | |
| AU2012902593A0 (en) | Improved Recombinant Viruses | |
| GB201115906D0 (en) | Escherichia coli vaccine combination | |
| GB201204851D0 (en) | Immunogenic composition |